Dublin, June 08, 2023 (GLOBE NEWSWIRE) -- The "China TAVR & TMV Market: Insights & Forecast with Potential Impact of COVID-19 (2023-2027)" report has been added to ResearchAndMarkets.com's offering.
China TAVR market is expected to reach US$2.60 billion in 2027, growing at a CAGR of 55.91%, for the duration spanning 2023-2027.
The TMV market in China is forecasted to reach US$1832.05 million in 2027, rising at a CAGR of 146.50%, for the time period of 2023-2027.
Factors such as growing prevalence of aortic stenosis, rise in approval of new TAVR products, rise in geriatric population and rapid urbanization would drive the growth of the market. However, the market growth would be challenged by risks associated with TAVR procedures and challenge of patient selection in TMVI.
A few notable trends may include rising penetration of TAVR and TMV procedures, decline in prices of transcatheter mitral valve procedures, upcoming major TMVI products and rise in complications in open-heart surgery.
Currently, interventional heart valve therapy is advancing rapidly and is considered as a safe and minimal invasive treatment suitable for elderly patients with high surgical risks, poor health and other complications. With technology development, indications for interventional therapy are broadening.
In particular, driven by China's favorable policy encouraging innovative medical devices, a growing number of medical device companies have joined the competition of R&D of transcatheter heart valve repair and replacement products in China. Growth in the R&D activities among major players in the country would drive the new products launch and would propel the TAVR and TMV market in China.
Scope of the report
- The report provides a comprehensive analysis of the China TAVR and TMV Market.
- The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
- The company profiles of leading players (Medtronic PLC, Edwards Lifesciences, Venus MedTech HangZhou Inc., MicroPort CardioFlow Medtech Corporation and Peijia Medical) are also presented in detail.
Key Target Audience
- TAVR and TMV Products Manufacturers
- Raw Material Suppliers
- End Users (Hospitals, Surgical centers and Medical Institutes)
- Research and Development Firms
- Medical Technology Companies
- Investment Banks
- Government Bodies & Regulating Authorities
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 51 |
| Forecast Period | 2023 - 2027 |
| Estimated Market Value (USD) in 2023 | $0.44 Billion |
| Forecasted Market Value (USD) by 2027 | $2.6 Billion |
| Compound Annual Growth Rate | 55.9% |
| Regions Covered | China |
Key Topics Covered:
1. Overview
2. Impact of COVID-19
3. China Market Analysis
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Growing Prevalence of Aortic Stenosis
4.1.2 Rise in Approval of New TAVR Products
4.1.3 Rise in Geriatric Population
4.1.4 Rapid Urbanization
4.2 Key Trends
4.2.1 Rising Penetration of TAVR and TMV Procedures
4.2.2 Decline in Prices of Transcatheter Mitral Valve Procedures
4.2.3 Upcoming Major TMVI Products
4.2.4 Rise in Complications in Open-heart Surgery
4.3 Challenges
4.3.1 Risks Associated with TAVR Procedures
4.3.2 Challenge of Patient selection in TMVI
5. Competitive Landscape
5.1 China Market
5.1.1 Key Players - Revenue Comparison
5.1.2 Key Players - R&D Expenditure Comparison
5.1.3 Key Players - Market Capitalization Comparison
5.1.4 Key Players - Second-generation TAVR Product Comparison
6. Company Profiles
Companies Mentioned
- 3M Company
- Medtronic PLC
- Edwards Lifesciences
- Venus MedTech HangZhou Inc.
- MicroPort CardioFlow Medtech Corporation
- Peijia Medical
For more information about this report visit https://www.researchandmarkets.com/r/8zkafo
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
